Home All Products TRZ
TRZ
TRZ

TRZ

Class: Dual GIP and GLP-1 receptor agonist (“twincretin”)
Amino Acids: 39
FDA Approvals:

  • May 2022 – Type 2 diabetes
  • November 2023 – Obesity management

Formulation: Subcutaneous injection, once-weekly dosing
Half-Life: ~5 days (via C20 fatty diacid albumin binding)

  • Weight Loss: Up to 22.5% reduction in body weight
  • Glycemic Control: HbA1c reductions of 1.87–2.58%; up to 62.4% achieve normoglycemia
  • Cardiometabolic Risk: Reduced blood pressure, triglycerides, and inflammatory markers
  • Hypoglycemia Risk: Fewer episodes compared to insulin therapies
  • Insulin Sensitivity: Improved metabolic function independent of weight loss
  • Convenient Dosing: Once-weekly injection; high adherence
  • GI Tolerability: Low gastrointestinal side effects; discontinuation rates 4.3–7.1%
  1. Nauck, M.A., et al. (2022). Cardiovascular Diabetology, 21(1), 169. DOI: 10.1186/s12933-022-01604-7
  2. Willard, F.S., et al. (2020). JCI Insight, 5(17), e140532. DOI: 10.1172/jci.insight.140532
  3. Frías, J.P., et al. (2021). NEJM, 385(6), 503-515. DOI: 10.1056/NEJMoa2107519
  4. Jastreboff, A.M., et al. (2022). NEJM, 387(3), 205-216. DOI: 10.1056/NEJMoa2206038
  5. Yang, J., et al. (2024). Frontiers in Pharmacology, 15, 1453825. DOI: 10.3389/fphar.2024.1453825.

$120.00

Per Unit
In stock

Free Shipping on All Orders $1000+